美国NDC复合药物数据库文件

药品名称：商品名称：药品NDC：报告期内： -格式:2020-5-3
NDC包装id：市场分类：活性成分：持证企业：

美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)

药品名称(分析)

商品名

药品NDC

专利人(分析)

报告期内

活性成分

市场分类

规格(分析)

NDC包装id

101018 NIACINAMIDE 4% / TACROLIMUS 0.1%

HUMAN COMPOUNDED DRUG

72934-5367

SKNV

2024-2

TACROLIMUS; NIACINAMIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.1 g/100 mL; 4 g/100 mL

72934-5367-2

121022 HYDROCORTISONE 2.5% / IODOQUINOL 1% / KETOCONAZOLE 2%

HUMAN COMPOUNDED DRUG

72934-2370

SKNV

2024-2

KETOCONAZOLE; HYDROCORTISONE; IODOQUINOL

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 g/100 mL; 2.5 g/100 mL; 1 g/100 mL

72934-2370-2

201070 BENZOCAINE 20% / LIDOCAINE 10% / TETRACAINE 10%

HUMAN COMPOUNDED DRUG

72934-2406

SKNV

2024-2

BENZOCAINE; LIDOCAINE; TETRACAINE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

20 g/100 mL; 10 g/100 mL; 10 g/100 mL

72934-2406-4

141062 HYDROCORTISONE 2.5% / HYDROQUINONE 4% / TRETINOIN 0.025%

HUMAN COMPOUNDED DRUG

72934-6388

SKNV

2024-2

HYDROQUINONE; TRETINOIN; HYDROCORTISONE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; .025 g/100 mL; 2.5 g/100 mL

72934-6388-2

121020 HYDROCORTISONE 2.5% / KETOCONAZOLE 2%

HUMAN COMPOUNDED DRUG

72934-2369

SKNV

2024-2

KETOCONAZOLE; HYDROCORTISONE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 g/100 mL; 2.5 g/100 mL

72934-2369-2

171083 IVERMECTIN 1% / METRONIDAZOLE 1% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-1400

SKNV

2024-1

NIACINAMIDE; IVERMECTIN; METRONIDAZOLE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; 1 g/100 mL; 1 g/100 mL

72934-1400-2

241019 LACTIC ACID 10% / UREA 40%

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

40 g/100 mL; 10 g/100 mL

72934-1412-4

141068 LACTIC ACID 10% / NIACINAMIDE 4%

HUMAN COMPOUNDED DRUG

72934-2391

SKNV

2024-1

NIACINAMIDE; LACTIC ACID

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 g/100 mL; 10 g/100 mL

72934-2391-2

221034 LIDOCAINE 5% / SALICYLIC ACID 40%

HUMAN COMPOUNDED DRUG

72934-1436

SKNV

2024-1

SALICYLIC ACID; LIDOCAINE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

40 g/100 mL; 5 g/100 mL

72934-1436-2

Norepinephrine Bitartrate

HUMAN COMPOUNDED DRUG

72055-017

Baycare Integrated Service Center, LLC /dba BayCare Central Pharmacy

2024-2

NOREPINEPHRINE BITARTRATE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

16 mg/250 mL

72055-017-01

Oxytocin

HUMAN COMPOUNDED DRUG

72055-018

Baycare Integrated Service Center, LLC /dba BayCare Central Pharmacy

2024-2

OXYTOCIN

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

30 U/500 mL

72055-018-01

Sugammadex

HUMAN COMPOUNDED DRUG

72055-015

Baycare Integrated Service Center, LLC /dba BayCare Central Pharmacy

2024-2

SUGAMMADEX

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

100 mg/2 mL

72055-015-01

Lidocaine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-110

STAQ Pharma Inc

2024-2

LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

9 mg/1 mL

73177-110-12

Lidocaine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-120

STAQ Pharma Inc

2024-2

LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

20 mg/1 mL

73177-120-02

Lidocaine Hydrochloride Epinephrine Bitartrate Tetracaine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-121

STAQ Pharma Inc

2024-2

EPINEPHRINE BITARTRATE; TETRACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.905 mg/1 mL; 5 mg/1 mL; 40 mg/1 mL

73177-121-19

Potassium Chloride

HUMAN COMPOUNDED DRUG

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

2 meq/1 mL

73177-127-05

Lidocaine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-118

STAQ Pharma Inc

2024-2

LIDOCAINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

10 mg/1 mL

73177-118-03

Dexmedetomidine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-123

STAQ Pharma Inc

2024-2

DEXMEDETOMIDINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

4 ug/1 mL

73177-123-02

Ketamine Hydrochloride

HUMAN COMPOUNDED DRUG

73177-155

STAQ Pharma Inc

2024-2

KETAMINE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

5 mg/1 mL

73177-155-27

Hydromorphone Hydrochloride

HUMAN COMPOUNDED DRUG

73177-141

STAQ Pharma Inc

2024-2

HYDROMORPHONE HYDROCHLORIDE

OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)

.1 mg/1 mL

73177-141-27

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：